Haemonetics Co. (NYSE:HAE) Director Pedro P. Granadillo sold 12,322 shares of the firm’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $114.50, for a total transaction of $1,410,869.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Pedro P. Granadillo also recently made the following trade(s):
- On Monday, September 17th, Pedro P. Granadillo sold 30,824 shares of Haemonetics stock. The shares were sold at an average price of $111.83, for a total transaction of $3,447,047.92.
Shares of Haemonetics stock traded down $3.47 on Friday, reaching $111.61. The stock had a trading volume of 667,800 shares, compared to its average volume of 461,515. The company has a quick ratio of 1.94, a current ratio of 2.92 and a debt-to-equity ratio of 0.47. Haemonetics Co. has a 1 year low of $53.74 and a 1 year high of $117.56. The company has a market cap of $5.95 billion, a P/E ratio of 59.68, a PEG ratio of 3.67 and a beta of 1.09.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The firm had revenue of $241.58 million for the quarter, compared to the consensus estimate of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.48 EPS. As a group, equities research analysts forecast that Haemonetics Co. will post 2.33 EPS for the current fiscal year.
A number of brokerages have recently issued reports on HAE. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Morgan Stanley lifted their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Haemonetics in a research report on Tuesday, August 7th. Barrington Research lifted their price objective on shares of Haemonetics from $90.00 to $118.00 and gave the stock an “outperform” rating in a research report on Thursday, August 9th. Finally, Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective on the stock in a research report on Friday, October 12th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $113.20.
Large investors have recently added to or reduced their stakes in the business. CIBC Asset Management Inc purchased a new stake in Haemonetics during the 3rd quarter worth approximately $219,000. Welch & Forbes LLC purchased a new stake in Haemonetics during the 3rd quarter worth approximately $229,000. Oakbrook Investments LLC purchased a new stake in Haemonetics during the 3rd quarter worth approximately $229,000. Wealth Alliance Advisory Group LLC purchased a new stake in Haemonetics during the 3rd quarter worth approximately $229,000. Finally, CIBC World Markets Inc. purchased a new stake in Haemonetics during the 3rd quarter worth approximately $233,000. 96.44% of the stock is currently owned by institutional investors.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Recommended Story: Buyback For Investors Defined
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.